학술논문
P.136 Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD
Document Type
Abstract
Author
Source
In Neuromuscular Disorders October 2022 32 Supplement 1:S104-S104
Subject
Language
ISSN
0960-8966